Value AD
CAN BE
ALTERNATIVE
INVESTMENT
CCRP Initiative: Countermeasures Against Chemical Threats (CounterACT) Therapeutics Discovery and Early-Stage Development (UG3/UH3 Clinical Trial Not Allowed)
PAR-22-209
National Institutes of Health
Funding Opportunity Number: PAR-22-209
Opportunity Category: Discretionary
CFDA Number(s): 93.113 -- Environmental Health,93.279 -- Drug Abuse and Addiction Research Programs,93.846 -- Arthritis, Musculoskeletal and Skin Diseases Research,93.853 -- Extramural Research Programs in the Neurosciences and Neurological Disorders,93.855 -- Allergy and Infectious Diseases Research,93.867 -- Vision Research
Cost Sharing or Matching Requirement: No
Posted Date: Jul 06, 2022 12:00:00 AM EDT
Closing Date: Oct 17, 2024 12:00:00 AM EDT
Award Ceiling: $350000
Award Floor: none
Eligible Applicants: Public housing authorities/Indian housing authorities,Special district governments,County governments,Independent school districts,For profit organizations other than small businesses,Public and State controlled institutions of higher education,Small businesses,City or township governments,Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education,Native American tribal organizations (other than Federally recognized tribal governments),State governments,Native American tribal governments (Federally recognized),Others (see text field entitled "Additional Information on Eligibility" for clarification),Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education,Private institutions of higher education
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Agency Name: National Institutes of Health
Description: This Funding Opportunity Announcement (FOA) solicits applications for the early-stage development of therapeutics to mitigate the adverse health effects resulting from toxic chemical exposure. Chemical threats are toxic compounds that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. They include specific chemical warfare agents, toxic industrial chemicals, pesticides, and pharmaceutical-based agents. The overall scope of this solicitation includes validation of therapeutic targets and preclinical characterization of lead compounds. The UG3 phase of this FOA supports target validation and characterization of initial lead compound(s); UH3 phase activities include candidate optimization and in vivo demonstration of activity and efficacy in relevant post-exposure models. At the conclusion of the overall UG3/UH3 funding period, projects are expected to deliver at least one well-characterized therapeutic candidate.
Grantor Contact Information: NIH OER Webmaster OERWebmaster03@od.nih.gov
